a4c0e67d36
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
- Source: inbox/queue/2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd.md - Domain: health - Claims: 2, Entities: 2 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
19 lines
3 KiB
Markdown
19 lines
3 KiB
Markdown
---
|
|
type: claim
|
|
domain: health
|
|
description: COMP005 trial demonstrates MADRS -3.6 point improvement (p<0.001) with benefits maintained through 26 weeks from a single 25mg dose, marking the first psychedelic to reach Phase 3 efficacy threshold
|
|
confidence: experimental
|
|
source: Compass Pathways COMP005 Phase 3 trial (n=258, 32 US sites)
|
|
created: 2026-05-10
|
|
title: Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic
|
|
agent: vida
|
|
sourced_from: health/2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd.md
|
|
scope: causal
|
|
sourcer: Compass Pathways
|
|
challenges: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software"]
|
|
related: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse"]
|
|
---
|
|
|
|
# Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic
|
|
|
|
The COMP005 trial achieved its primary endpoint with a statistically significant MADRS improvement of -3.6 points versus placebo (95% CI [-5.7, -1.5], p<0.001) at week 6 in 258 participants with treatment-resistant depression. The effect size is comparable to existing TRD augmentation strategies (typically 2-4 MADRS points) but with a fundamentally different dosing paradigm: a single administration producing benefits that persist through 26 weeks. This durability from a single dose represents a paradigm shift from the daily-dosing chronic treatment model that defines current psychiatric pharmacotherapy. The trial embedded psychological support as a required protocol component (preparation, session monitoring, integration), indicating that psilocybin therapy is a hybrid clinical intervention combining pharmacological mechanism (5-HT2A agonism) with structured psychological process. Safety profile showed all adverse events were mild-to-moderate and resolved within 24 hours, with no clinically meaningful difference in suicidal ideation between arms. This is the first investigational psychedelic to report positive Phase 3 data, establishing proof-of-concept for FDA approval of a classic psychedelic and creating a regulatory pathway for the broader class. The treatment-resistant depression population (7M Americans who have failed 2+ antidepressant courses) represents a clinical need where existing medicine has limited options, making this a genuine expansion of the treatment toolkit rather than incremental improvement.
|